Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol

Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol

The Coronavirus disease (COVID-19) pandemic is causing millions of infections and hundreds of thousands of deaths worldwide. Cumulative clinical and laboratory evidence suggest that a subset of patients with severe COVID-19 may develop a cytokine storm syndrome during the course of the disease, with...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Enrico Capochiani, Bruno Frediani, Giorgio Iervasi, Aldo Paolicchi, Spartaco Sani, P Roncucci, Annarosa Cuccaro, Federico Franchi, Federico Simonetti, Davide Carrara, Ilaria Bertaggia, Daniela Nasso, Rossella Riccioni, Sabino Scolletta, Serafina Valente, Edoardo Conticini, Alessandro Gozzetti, Monica Bocchia
Formatua: Artigo
Hizkuntza:ingelesa
Argitaratua: 2020
Sarrera elektronikoa:https://doi.org/10.3389/fmed.2020.00466
https://www.frontiersin.org/articles/10.3389/fmed.2020.00466/pdf
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Internet

https://doi.org/10.3389/fmed.2020.00466
https://www.frontiersin.org/articles/10.3389/fmed.2020.00466/pdf

Antzeko izenburuak